TFF Pharmaceuticals to Participate at the 34th Annual Roth Conference
11. März 2022 07:05 ET
|
TFF Pharmaceuticals, Inc.
AUSTIN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals to Hold Fourth Quarter and Full Year 2021 Financial and Business Results Conference Call on March 24, 2022
09. März 2022 16:05 ET
|
TFF Pharmaceuticals, Inc.
AUSTIN, Texas, March 09, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement
01. März 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
Catalent to collaborate on the scalability and manufacturing for TFF Pharmaceuticals’ proprietary Thin Film Freezing technologyCollaboration focused on development of dry powder formulations of...
TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2
24. Februar 2022 09:27 ET
|
TFF Pharmaceuticals, Inc.
Inhaled Niclosamide Demonstrates Potent Activity Against Omicron Variant Dosing of Inhaled Niclosamide Estimated to Produce Concentrations in Excess of Effective Dose Expecting to Complete Phase 1...
TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19
27. Januar 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
Complete Safety Data Anticipated by End of 1Q 2022 Safety Management Committee Has Recommended 12 mg as Phase 2 Dose Niclosamide is a Potent Inhibitor of SARS-CoV-2 with Activity Against Multiple...
TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients
21. Dezember 2021 08:00 ET
|
TFF Pharmaceuticals, Inc.
Final Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive Pulmonary Aspergillosis (IPA), Including Patients with Mild to Moderate...
TFF Pharmaceuticals Hosting Science Day on December 13, 2021
06. Dezember 2021 08:00 ET
|
TFF Pharmaceuticals, Inc.
AUSTIN, Texas, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
15. November 2021 16:01 ET
|
TFF Pharmaceuticals, Inc.
Positive Updates Announced for Inhaled Voriconazole and Tacrolimus Programs;Both Programs Advancing into Phase 2 Testing Continued Progress with Partnered Antiviral Programs for AUG-3387 and...
TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients
08. November 2021 08:03 ET
|
TFF Pharmaceuticals, Inc.
Initial data from Phase 1b showed Voriconazole Inhalation Powder is Well Tolerated in Asthma Patients Data Supports Progress to Phase 2 and Inclusion of Patients with Asthma AUSTIN, Texas, Nov. ...
TFF Pharmaceuticals to Participate in the 12th Annual Jefferies London Healthcare Conference 2021
08. November 2021 08:00 ET
|
TFF Pharmaceuticals, Inc.
AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...